GAIN-(L): Efficacy and biomarker findings of RG7160 (GA201), a novel, dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with first-line cisplatin and pemetrexed in metastatic nonsquamous NSCLC.

James Spicer, Luis Paz‐Ares, Lionel Bosquée et al.|Journal of Clinical Oncology|2012

Cited by 0